Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Plain-language summary
This Phase 2 trial is evaluating golidocitinib with azacytidine and chidamide as a treatment for people newly diagnosed with peripheral T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
golidocitinib with azacytidine and chidamide (DRUG): In Phase I, a "3+3" dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD). In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma
- Drugs / treatments
- golidocitinib with azacytidine and chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details